Diabetes Mellitus
Conditions
Keywords
Insulin secretion
Brief summary
The investigator will examine the effect of a single dose of pyridostigmine, AchE inhibitor on insulin secretion in healthy subjects. Each subject will undergo an intravenous glucose tolerance test (IVGTT) where IV glucose will be administered and the glucose excursion and insulin secretion response will be evaluated by measuring insulin and glucose at different time points. The test will be carried out twice, once without and once with the administration of a single dose of Pyridostigmine on two separate days. The investigator hypothesizes that inhibiting AChE will potentiate insulin secretion.
Interventions
DRUGPyridostigmine
single oral dose of 60 mg pyridostigmine tablet
Sponsors
American Diabetes Association
University of Miami
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* 18 years and older
Exclusion criteria
* BMI \>30 Kg/m2 * fasting glucose \>100 * Glycohemoglobin (Hemoglobin A1C) 5.7% or more * History of asthma * Use of medications that may interfere with glucose metabolism
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| First phase insulin response to IV glucose infusion | -10, -4, 1, 2, 3, 4, 5, 6, 8, and 10 minutes | Insulin positive incremental area under the curve and the sum of plasma insulin values at 1 minute and 3 minutes after IV glucose infusion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Glucose excursion after IV glucose infusion | -10, -4, 1, 2, 3, 4, 5, 6, 8, and 10 minutes | Glucose positive incremental area under the curve |
Countries
United States
Outcome results
None listed